SELLAS Life Sciences Group, Inc. (SLS) Stock Analysis — Probabli.AI
AI-powered analysis for SLS (SELLAS Life Sciences Group, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $5.96 · Market cap: $921.2M · AI outlook: Bullish
SELLAS Life Sciences Group Inc., a biopharmaceutical company traded on the NCM exchange, is a speculative yet promising investment driven by its innovative approaches in oncology. Recent headlining advancements, equity strength, and strong analyst sentiment present an attractive short-term opportunity, although clinical delays and inherent risks underline the necessity of caution. Long-term…
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 1-year price estimates — P10: $5 / P50: $7 / P90: $9
- The bullish outlook is based on recent positive data from phase 2 trials and equity financing to advance clinical trials. The analyst consensus being a strong buy with a mean target of $7.00 suggests bullish sentiment.…
5-Year Outlook
- Bull 70% · Neutral 20% · Bear 10%
- 5-year price estimates — P10: $7 / P50: $15 / P90: $23
SWOT Highlights
- Strength: Strong clinical trial results in phase 2
- Strength: Supportive equity financing setup
- Risk: Clinical trial delays
- Risk: Currently unprofitable
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
1 Wall Street analyst rate SLS a STRONG BUY with a mean price target of $7.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
SLS forecast details · SLS sentiment details · SLS insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.